Novel Compound HJC0416 Attenuates Hepatic Fibrosis via HSP90/NF-κB-Associated Mechanism

Area of Science:

• Hepatology and Molecular Biology
• Cellular Signaling and Inflammation

Background:

• Chronic liver disease involves fibrogenesis driven by hepatic stellate cells (HSCs) and regulated by the NF-κB pathway.
• HSCs' survival and activation are dependent on NF-κB signaling.
• Previous research identified HJC0416 as a STAT3 inhibitor with anti-inflammatory effects in HSCs, reducing viability and ECM production, but its antifibrotic mechanism was unclear.

Purpose of the Study:

• To investigate the antifibrotic mechanism of HJC0416 in hepatic stellate cells.
• To examine the effects of HJC0416 on the NF-κB pathway and its association with Heat Shock Protein 90 (HSP90).

Main Methods:

• Human activated HSC line LX-2 was treated with HJC0416 or 17-AAG (HSP90 inhibitor) and exposed to TNFα.
• Western blot and immunofluorescence assays were used to analyze protein expression and localization.

Main Results:

• HJC0416 suppressed TNFα-induced IκBα phosphorylation, NF-κB p65 nuclear translocation, and DNA binding activity.
• HJC0416 dose-dependently reduced the expression of HSP90 interacting proteins, including FAK, IKKα, and STAT3.
• The HSP90 inhibitor 17-AAG also inhibited NF-κB activation and collagen production.

Conclusions:

• Heat Shock Protein 90 (HSP90) may mediate HJC0416's inhibition of NF-κB activity.
• HJC0416 demonstrates potential as a therapeutic agent for liver fibrosis.